BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, April 20, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 7, 1998

View Archived Issues

Imutec reports positive phase I/II results for Virulizin

Read More

Maracenines: isolation and characterization of new antibacterial agents

Read More

MMP inhibitors in early development at British Biotech

Read More

Antiadhesion agents prepared and evaluated at Hoechst

Read More

First small-molecule G-CSF mimic synthesized by SB-Ligand team

Read More

PJ-1, an antiplatelet compound with a dual mechanism of action

Read More

Positive clinical trial results reported for HTF-919

Read More

Substituted pyrimidines from Amgen inhibit cytokine production

Read More

Bradykinin B2 antagonists in the pipeline at Fournier

Read More

Maruishi licenses rights to Chirocaine in Japan

Read More

Broad-spectrum parenteral cephalosporin launched this week in Japan

Read More

Zeneca acquires Australian pharmaceuticals business

Read More

EMD-122946, a potent and orally active ETA antagonist looks promising in preclinical studies

Read More

L-375052, a potent thrombin inhibitor with improved pharmacokinetics

Read More

Isoxazoline- and isoxazole-containing factor Xa inhibitors prepared by DuPont

Read More

Candidate oral fibrinogen receptor antagonist presented by Uriach at ACS meeting

Read More

Potent, orally active, second-generation neuroimmunophilin from Guilford

Read More

Invicorp trial results highlighted at recent congress

Read More

DMP-695: ACS debut for new, orally active CRF1 antagonist

Read More

MDX-CD4 development progresses, triggering milestone payment from Eisai

Read More

Lilly and Synaptic enter late-stage trials with antimigraine agent

Read More

Oral osteoporosis product developed by Lilly and Emisphere heads for clinical trials

Read More

Efficacy and safety of sublingual apomorphine in treatment of MED

Read More

Hyaluronic acid oligosaccharides inhibit tumor metastasis

Read More

Bayer, Fournier to copromote statin in some EU countries

Read More

FDA indicates approvability of DepoCyt for neoplastic meningitis from lymphomas

Read More

Enbrel efficacy demonstrated in juvenile RA patients

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 17, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • Novel caspase-2 inhibitor shows in vivo neuroprotective effects

    BioWorld Science
    Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing